about
Homozygous deletion of the activin A receptor, type IB gene is associated with an aggressive cancer phenotype in pancreatic cancerFrequent amplification of ORAOV1 gene in esophageal squamous cell cancer promotes an aggressive phenotype via proline metabolism and ROS production.Synergistic antitumor effects of S-1 with eribulin in vitro and in vivo for triple-negative breast cancer cell lines.KIAA1199 interacts with glycogen phosphorylase kinase β-subunit (PHKB) to promote glycogen breakdown and cancer cell survival.Melanoma transition is frequently accompanied by a loss of cytoglobin expression in melanocytes: a novel expression site of cytoglobin.Extended RAS and BRAF Mutation Analysis Using Next-Generation Sequencing.Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A.Tumor vaccines in renal cell carcinoma.Osteopontin knockdown in the kidneys of hyperoxaluric rats leads to reduction in renal calcium oxalate crystal deposition.MEK inhibitors against MET-amplified non-small cell lung cancerFGFR gene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanib.Increased FGF19 copy number is frequently detected in hepatocellular carcinoma with a complete response after sorafenib treatment.Clonal composition of human ovarian cancer based on copy number analysis reveals a reciprocal relation with oncogenic mutation status.Sensitivities to various epidermal growth factor receptor-tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor-tyrosine kinase inhibitor?Identification of Programmed Death Ligand 1-derived Peptides Capable of Inducing Cancer-reactive Cytotoxic T Lymphocytes From HLA-A24+ Patients With Renal Cell Carcinoma.EGFR and HER2 signals play a salvage role in MEK1-mutated gastric cancer after MEK inhibition.New polycomb group protein enhancer of zeste homolog (EZH) 2-derived peptide with the potential to induce cancer-reactive cytotoxic T lymphocytes in prostate cancer patients with HLA-A3 supertype alleles.Chronic nicotine exposure mediates resistance to EGFR-TKI in EGFR-mutated lung cancer via an EGFR signal.Activated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in ALK-positive non-small cell lung cancer.Activin signal promotes cancer progression and is involved in cachexia in a subset of pancreatic cancer.Inhibition of β-Catenin enhances the anticancer effect of irreversible EGFR-TKI in EGFR-mutated non-small-cell lung cancer with a T790M mutation.MEK inhibitor for gastric cancer with MEK1 gene mutations.Hypoxia induces resistance to ALK inhibitors in the H3122 non-small cell lung cancer cell line with an ALK rearrangement via epithelial-mesenchymal transition.Identification of erythropoietin receptor-derived peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes from HLA-A24(+) patients with renal cell carcinoma.Antitumor activity of BIBF 1120, a triple angiokinase inhibitor, and use of VEGFR2+pTyr+ peripheral blood leukocytes as a pharmacodynamic biomarker in vivo.Role of syndecan-1 (CD138) in cell survival of human urothelial carcinoma.A novel human AlkB homologue, ALKBH8, contributes to human bladder cancer progression.Evaluation of in vivo responses of sorafenib therapy in a preclinical mouse model of PTEN-deficient of prostate cancer.Clinicopathological and genetic differences between low-grade and high-grade colorectal mucinous adenocarcinomas.Androgen deprivation induces phenotypic plasticity and promotes resistance to molecular targeted therapy in a PTEN-deficient mouse model of prostate cancer.Preclinical Remodeling of Human Prostate Cancer through the PTEN/AKT Pathway.Efficacy of targeted AKT inhibition in genetically engineered mouse models of PTEN-deficient prostate cancerCarvedilol protects tubular epithelial cells from ischemia-reperfusion injury by inhibiting oxidative stress.Performance of a novel KRAS mutation assay for formalin-fixed paraffin embedded tissues of colorectal cancer.Hypoxia-inducing factor (HIF)-1α-derived peptide capable of inducing cancer-reactive cytotoxic T lymphocytes from HLA-A24+ patients with renal cell carcinoma.Effects of the Rho kinase inhibitor, hydroxyfasudil, on bladder dysfunction and inflammation in rats with HCl-induced cystitis.Immunological evaluation of personalized peptide vaccination monotherapy in patients with castration-resistant prostate cancer.Prostate cancer immunotherapy: where are we and where are we going?Significance of FGF9 gene in resistance to anti-EGFR therapies targeting colorectal cancer: A subset of colorectal cancer patients with FGF9 upregulation may be resistant to anti-EGFR therapies.Functional Analyses of Mutations in Receptor Tyrosine Kinase Genes in Non-Small Cell Lung Cancer: Double-Edged Sword of DDR2.
P50
Q33718622-EAD3F7B0-00FC-481B-866D-C24DDF0D6BDEQ33917534-85048CF6-C484-4B99-82F8-06B60774E972Q34062522-3336D223-501B-404F-A301-DF9D1F200FC0Q34334493-8786C65E-9196-45F1-AC61-00C5E93598B5Q35145371-36B155FD-A6A7-4187-B068-52B940865D39Q35587176-F8F79BEB-B680-4A79-BEB0-3BC0D827863CQ36351290-4E2D3FC2-0284-4CD6-A7DA-7774A310AC24Q37107926-5E9FC274-8599-4FCA-B67F-02B2340C47E2Q37164533-C748A199-AD69-42D0-A4C0-E761CC6CE194Q37427045-6000C422-BA5C-4DA0-8965-80F0D81C9582Q37462489-6F7CDF82-8DCA-4B0F-B8FD-2BF41BC5E3FCQ37580172-9222513C-181F-4E81-B9D0-D4EA02648584Q38666582-A509EC03-45F8-4A68-BF3D-B926DAD5DB1CQ38767492-366D02D2-8326-4B20-A471-B0E437202C0DQ38844569-735DC4B4-536D-4249-9594-88E6D7E898D3Q38863220-E0D7B5B8-0ECD-4CFB-B798-78EEBDE7B7DCQ38893658-2CC5DF81-21B0-4ABA-9A99-C4A45502791FQ38907034-A2086A46-F235-465E-845A-16C83505AFDFQ38929017-0CD05426-D2B9-4136-B03A-7458FC37C8FEQ38934921-AFE2D4F3-50A4-48AB-AE25-C97A8BDDB7B4Q38941502-18234D76-5A6B-4E29-BA7F-B6A9B93F53CFQ38953493-083FBCBD-AD5A-4324-A8DB-C0872B337283Q38968478-D8798D01-A19D-4851-85D3-E217F8E9759EQ39019657-2A151028-B38C-45E8-BF92-0D74ADB0233AQ39623814-A7C284F7-5737-46A5-B675-DE0AFC20E520Q39782934-91A097B8-A603-4766-8E5B-D056D2491288Q39871786-70D22080-B0F3-4552-A57E-4A2552D2B78DQ40880050-EE1BCA10-A8AF-40C8-8594-4D00CFE7EA55Q41197354-1AB8649E-6AE4-49DA-8A4F-8C2C015C4367Q41865902-32E18C88-6CFD-48AC-92B8-9DD4401C22B7Q42014039-186EC301-75E7-4806-BB41-33AB544A904BQ42039942-5B06EDBF-DCA5-4D63-A765-B0FE75C00F08Q42859088-1E1DCD20-6678-46AC-ABA8-6D2A6AD0B3C2Q43136720-2C1D0A9B-ECC3-4753-8043-0D5B06D2D524Q51175521-0DDB2B0C-EECB-4126-B636-F52DF30A192BQ51272863-46399C6E-E800-4A0A-AD16-BFB873B88344Q51786076-9FD9B7D0-7C4A-4174-9670-5B857BAA78F9Q52446870-8975FE6B-E14B-4796-886B-DB2887915B13Q53164323-6104A678-5969-48BE-80B8-CA61BB26E8B1Q55031467-8D98EFB4-A4A2-4C71-A471-0B590791F099
P50
description
researcher ORCID ID = 0000-0002-4011-6572
@en
wetenschapper
@nl
name
Marco A de Velasco
@ast
Marco A de Velasco
@en
Marco A de Velasco
@es
Marco A de Velasco
@nl
type
label
Marco A de Velasco
@ast
Marco A de Velasco
@en
Marco A de Velasco
@es
Marco A de Velasco
@nl
prefLabel
Marco A de Velasco
@ast
Marco A de Velasco
@en
Marco A de Velasco
@es
Marco A de Velasco
@nl
P106
P1153
24766374500
P31
P496
0000-0002-4011-6572